Manufacturing milestone secured as MagSense® advances toward Phase 2
Following the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application on 1 June 2026, Imagion Biosystems (ASX: IBX) has entered into a Master Service Agreement with nanoComposix, a specialty nanoparticle Contract Development and Manufacturing Organisation (CDMO), to resume nanoparticle manufacturing capabilities.
FDA clearance for the Phase 1b/2 trial was issued on 1 June 2026 via a Study May Proceed Notice, assigning IND number 165081 and confirming the regulatory pathway that makes this manufacturing agreement a directly actionable next step.
This is not a first-time arrangement. nanoComposix, a Fortis Life Sciences company, previously supported production of the MagSense® HER2 imaging agent during the successfully completed Phase 1 study and for the investigational product planned for the pending Phase 1b/2 study.
Under the agreement, Imagion will provide its proprietary nanoparticle synthesis equipment, software, and procedures to nanoComposix, which will manufacture pharmaceutical-grade material under Imagion’s direction. The model is designed to keep operational costs low while advancing MagSense® toward potential commercialisation.
When big ASX news breaks, our subscribers know first
What is a CDMO and why does it matter for IBX investors?
A Contract Development and Manufacturing Organisation is a specialist third-party company that produces pharmaceutical or biotech materials on behalf of a client under contract. Clinical-stage companies like Imagion typically engage CDMOs instead of building their own facilities, preserving capital for research and development.
Good Manufacturing Practice (GMP) refers to a quality assurance framework that ensures pharmaceutical-grade material is produced consistently and to regulatory standards. For Imagion, GMP-quality output from nanoComposix aims to align with U.S. FDA product quality requirements, a prerequisite for any future New Drug Application (NDA) submission.
The CDMO model delivers several specific benefits for Imagion:
- Eliminates fixed costs associated with investing in a dedicated manufacturing facility and staffing
- Imagion retains control by providing its proprietary nanoparticle synthesis equipment, software, and procedures
- GMP-quality output aims to align with U.S. FDA product quality requirements
- Supports the potential NDA submission pathway by establishing product specifications and shelf-life early
- Positions the company well for any potential partnering transaction
Strategic fit — supporting the full MagSense® pipeline
The core nanoparticle manufactured under this agreement is the base component of all MagSense® imaging agents across Imagion’s three cancer programmes: HER2+ breast cancer, prostate cancer, and ovarian cancer. Resuming manufacturing capabilities therefore underpins the entire platform, not just the lead asset.
In the near term, nanoComposix will focus on establishing a robust manufacturing protocol to meet regulatory requirements for the MagSense® drug product and to supply any additional MagSense® HER2 investigational product that may be needed for the planned Phase 2 clinical trial. Manufacturing will also support research and development needs for the prostate and ovarian cancer programmes as and when those programmes are advanced, subject to the availability of funds.
Ward Detwiler, President of Imagion’s US Operations
“Establishing robust nanoparticle production capabilities is extremely important for our future. The core particles are a key component of our proprietary MagSense® technology and, therefore, essential to the long-term success of our business. We’re very pleased to be partnering with nanoComposix at this time to support our business initiatives.”
| Cancer Indication | Development Stage | Manufacturing Relevance | Next Milestone |
|---|---|---|---|
| HER2+ Breast Cancer | Phase 1 complete / Phase 1b/2 planned | Phase 2 trial supply | Phase 1b/2 study commencement |
| Prostate Cancer | Preclinical / R&D | R&D supply (subject to funding) | Programme advancement |
| Ovarian Cancer | Preclinical / R&D | R&D supply (subject to funding) | Programme advancement |
Investment thesis — building the foundation for commercialisation
Three investor-relevant themes converge in this announcement. The CDMO model keeps the cost structure lean by avoiding fixed manufacturing overheads. Developing robust manufacturing processes early ensures that product specifications and shelf-life are well characterised ahead of a potential NDA submission, which the company notes helps to avoid delays in the marketing authorisation process. The announcement also explicitly states that implementing this programme positions the company well and “will likely add value to any potential partnering transaction.”
With manufacturing capabilities now in place, the next clinical catalyst for investors to monitor is the commencement of the planned Phase 1b/2 study in HER2+ breast cancer. The announcement does not provide specific dates for that study’s start, but the manufacturing protocol being established is a prerequisite step on that path.
For investors tracking the full sequence of steps between FDA clearance and first patient enrolment, our detailed coverage of trial site activation and CRO engagement sets out the outstanding startup steps, including IRB approvals, ClinicalTrials.gov registration, and investigational product shipment across seven prospective US sites.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to get started today.